Case Reports in Psychiatry
Volume 2020 (2020), Article ID 8839984, 3 pages
https://doi.org/10.1155/2020/8839984

Case Report

An Increased Presence of Male Personalities in Dissociative Identity Disorder after Initiating Testosterone Therapy

Monique Mun, Mohan Gautam, Renee Maan, and Bassem Krayem

Henry Ford Health System, Department of Psychiatry, 1 Ford Place, 1C-09 Detroit, Michigan, USA, 48202

Correspondence should be addressed to Monique Mun; mmun1@hfhs.org

Received 20 June 2020; Accepted 28 September 2020; Published 5 October 2020

Academic Editor: Michael Kluge

Copyright © 2020 Monique Mun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Patients with gender dysphoria (GD) report significant dissociative symptoms and are found to have a high prevalence of a dissociative disorder of any kind. When GD patients elect to undergo cross-sex hormone therapy, there is a significant reduction in dissociative symptoms. However, to the best of our knowledge, there are no known case reports that describe an alteration of personalities in dissociative identity disorder after initiating cross-sex hormone therapy. Thus, we present a case of a 20-year-old transgender male with GD, whom after initiating cross-sex hormone therapy with testosterone experienced an increased presence of his existing male personalities.

1. Introduction

Gender dysphoria (GD) is defined in the DSM-V as significant distress due to an incongruence between one’s experienced or expressed gender and one’s assigned gender. It has a prevalence ranging from 0.5 to 1.3% in the United States [1]. Patients with GD report significant dissociative symptoms, such as depersonalization/derealization, absorption/imaginativeness, and conversion [2]. Thus, patients with GD have a high prevalence of a dissociative disorder of any kind (29.6%) [3]. When GD patients elect to undergo cross-sex hormone therapy, there is a significant reduction in dissociative symptoms [4]. However, to the best of our knowledge, there are no case reports that describe an alteration of personalities in dissociative identity disorder after initiating cross-sex hormone therapy. Thus, we present a case of a 20-year-old transgender male with GD, whom after initiating cross-sex hormone therapy with testosterone, experienced an increased presence of his existing male personalities.

2. Case

A 20-year-old transgender male with GD, undergoing cross-sex hormone therapy with testosterone, with past psychiatric history of dissociative identity disorder (DID), PTSD, and depression, was admitted to our inpatient psychiatric hospital after endorsing suicidal ideations and homicidal ideations towards others. This is context to significant distress from recently switching to one of his personalities. Family history was positive for depression in his mother and sister. Labs were unremarkable, except for elevated hemoglobin (16.7 g/dL), elevated hematocrit (48.7%), and elevated RBC count (6.12 M/μL). Urine drug screen was positive for cocaine, amphetamine, and benzodiazepine. The patient did not recall use of these substances, citing they were done as his most recent personality, Dexter.

The patient has a history of sexual abuse by his mother’s boyfriend from when he was 3 years old. He was subsequently diagnosed with PTSD and depression in his early adolescence. Although he no longer endorsed having nightmares, he continued to have intrusive-type symptoms of PTSD and a negative emotional state of anger and fear. While he was seeking outpatient therapy for PTSD and depression, his therapist diagnosed him with DID. Although he was born as the female sex, he identified having 6 personalities, most of whom are the male gender.

The patient started testosterone therapy two years prior to presentation, which has alleviated his GD symptoms. However, since starting testosterone, he noticed an increased presence of two existing personalities, both of whom are male: (1) Dexter, a personality who is aggressive and hostile and has violent thoughts—he uses illicit drugs; and (2) Bad, a personality who is evil and destructive—he throws furniture when he is angry and even tried to assault his girlfriend.

3. Discussion

DID, formerly known as multiple personality disorder, falls under the category of dissociative disorders in the DSM-V, alongside dissociative amnesia, depersonalization/derealization disorder, other specified dissociative disorder, and other unspecified dissociative disorder [5]. Dissociative disorders have a prevalence of 5-10% in the general population [6]. The hallmark of dissociative disorders is “an interruption and/or discontinuity in the normal integration of consciousness, memory, self-identity and subjective identity, emotion, perception, body identity, motor control and behavior” [6]. There are various factors that may confound or exacerbate symptoms of dissociative disorders, such as drugs of abuse, comorbid diagnoses with dissociative features, such as PTSD, and utilization of hormone therapy.

3.1. Drugs of Abuse and Dissociation

Drugs of abuse have been known to induce symptoms of dissociation that resemble dissociative disorders. Although the patient denied consistent drug use, his UDS was positive for cocaine, amphetamine, and benzodiazepine. A study by Kloet D et al. revealed that participants who were administered cannabis (THC 300 μg/kg), MDMA (single doses of 25, 50 or 100 mg), or cocaine (HCl 300 mg) all had a significant increase in dissociative symptoms compared to placebo, as measured by the Clinician-Administered Dissociative States Scale (CADSS) [7]. Specifically, the most profound effects were found with cannabis and MDMA; the effect of MDMA on dissociative symptoms was dose-dependent [7]. Similar to cocaine, stimulants such as dexamphetamine and methylphenidate can also increase rates of dissociation and psychedelic state [8]. Benzodiazepines are used with caution in patients with dissociative disorders due to its potential to exacerbate symptoms of dissociation [9].

3.2. sPTSD and Dissociation

There is considerable overlap between DID and PTSD. They share a common risk factor of childhood trauma. The DSM-5 added a dissociative subtype to PTSD to capture patients with PTSD with a predominance of depersonalization/derealization symptoms and emotional detachment [5]. The prevalence of those with PTSD dissociative type and any type of dissociative disorder was as high as 54% [10]. Research has established a difference in physiologic and neural response to traumatic memories between dissociative type PTSD and those with nondissociative PTSD [11]. However, distinguishing between PTSD dissociative subtype and dissociative disorders relies on a structured clinical interview.

3.3. Testosterone and Dissociation

The psychiatric effects of androgens on mood are well-studied. Androgens are known to be associated with an increase in euphoria and energy but also irritability, violence, and hostility [12]. Specifically, testosterone acts in the subcortical structures of the hypothalamus and amygdala, where aggression and emotions are localized. The prefrontal cortex interprets and regulates aggression and emotions. High levels of testosterone downregulate the prefrontal cortex, resulting in an increased expression of aggression [13]. However, a research gap remains regarding effects of testosterone on dissociative symptoms and recollection of traumatic events. It is possible that initiating testosterone altered his experience of trauma recollection. In other words, perhaps, the patient’s more masculine alters are a reflection of increased testosterone in patient’s utilization of dissociation to manage traumatic recollections/events. This would be relevant because LGBTQ-based discrimination increases overall traumatization which has relevant implications in exacerbation of dissociation and its lasting impacts [14]. This becomes especially pertinent for this patient as those with worse emotional dysregulation are associated with more severe dissociation phenomena [15].

3.4. Treatment Recommendations

Treatment recommendation for DID is intensive individual psychotherapy that focuses on recognizing and encouraging the cooperation between personalities and adapting new coping skills [6]. Although there is not one psychotherapy modality that is recommended, psychodynamic psychotherapy and hypnotic interventions have been frequently used [6]. We recommended that the patient continues psychotherapy with his outpatient therapist, whom he was seeing regularly and had built rapport with. Comorbid diagnoses should be addressed and treated to reduce risk of suicidality. The patient’s comorbid diagnoses of PTSD and depression were treated with venlafaxine after failing two previous trials of SSRIs. Venlafaxine was titrated to 225 mg daily. Substance use rehab was offered to the patient; however, he declined, citing he does not use substances consistently.

4. Conclusion

In summary, the present case reveals a correlation of testosterone therapy with dissociative symptoms. Although the patient reported a reduction in distress of his physical body after initiation of testosterone therapy, he reported an increase in hostility and violence, as well as an increased predominance of existing male alters. One cannot rule out the possibility of confounding factors that may have exacerbated or altered the patient’s dissociative symptoms, such as substance use and clinical overlap of PTSD. Yet, there still exists a scarcity of literature that describes the effects of testosterone on dissociative symptoms. Areas of further research may focus on effects of testosterone on the severity of dissociative symptoms, the frequency of switching personalities, and changes to the alters. Similarly, the effects of other neurochemical compounds, such as estrogen, on dissociative symptoms are another area of potential research.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

K. J. Zucker, “Epidemiology of gender dysphoria and transgender identity,” Sexual Health, vol. 14, no. 5, pp. 404–411, 2017.

A. Kersting, M. Reutemann, U. Gast et al., “Dissociative disorders and traumatic childhood experiences in transsexuals,” The Journal of Nervous and Mental Disease, vol. 191, no. 3, pp. 182–189, 2003.

M. Colizzi, R. Costa, and O. Todarello, “Dissociative symptoms in individuals with gender dysphoria: is the elevated prevalence real?” Psychiatry Research, vol. 226, no. 1, pp. 173–180, 2015.

E. Gómez-Gil, L. Zubiaurre-Elorza, I. Esteva et al., “Hormone-treated transsexuals report less social distress, anxiety and depression,” Psychoneuroendocrinology, vol. 37, no. 5, pp. 662–670, 2012.

American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM-5, American Psychiatric Association, Arlington, VA, 2017.

M. J. Romero-López, “Una revisión de los trastornos disociativos; de la personalidad múltiple al estrés postraumático,” Anales de Psicología, vol. 32, no. 2, pp. 448–456, 2016.

D. van Heugten-van der Kloet, T. Giesbrecht, J. van Wel et al., “MDMA, cannabis, and cocaine produce acute dissociative symptoms,” Psychiatry Research, vol. 228, no. 3, pp. 907–912, 2015.

J. Van Wel, D. Spronk, K. Kuypers et al., “Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity,” 2015, https://www.ncbi.nlm.nih.gov/pubmed/25572345.

J. P. Gentile, K. S. Dillon, and P. M. Gillig, “Psychotherapy and Pharmacotherapy for Patients with Dissociative Identity Disorder,” Innovations in Clinical Neuroscience, vol. 10, no. 2, pp. 22–29, 2013.

S. Swart, M. Wildschut, N. Draijer, W. Langeland, and J. H. Smit, “Dissociative subtype of posttraumatic stress disorder or PTSD with comorbid dissociative disorders: comparative evaluation of clinical profiles,” Psychological Trauma: Theory, Research, Practice, and Policy, vol. 12, no. 1, pp. 38–45, 2020.

J. van Huijstee and E. Vermetten, “The dissociative subtype of post-traumatic stress disorder: research update on clinical and neurobiological features,” in Behavioral Neurobiology of PTSD, pp. 229–248, Springer, 2017.

T.-P. Su, M. Pagliaro, P. J. Schmidt, D. Pickar, O. Wolkowitz, and D. R. Rubinow, “Neuropsychiatric effects of anabolic steroids in male normal volunteers,” JAMA, vol. 269, no. 21, pp. 2760–2764, 1993.

M. L. Batrinos, “Testosterone and aggressive behavior in man,” International Journal of Endocrinology & Metabolism, vol. 10, no. 3, pp. 563–568, 2012.

L. Keating and R. T. Muller, “LGBTQ+ based discrimination is associated with ptsd symptoms, dissociation, emotion dysregulation, and attachment insecurity among LGBTQ+ adults who have experienced trauma,” Journal of Trauma & Dissociation, vol. 21, no. 1, pp. 124–141, 2019.

A. Powers, D. Cross, N. Fani, and B. Bradley, “PTSD, emotion dysregulation, and dissociative symptoms in a highly traumatized sample,” Journal of Psychiatric Research, vol. 61, pp. 174–179, 2015.